Enhertu is the first approved therapy targeted to patients with the HER2-low breast cancer subtype, which is a newly defined subset of HER2-negative breast cancer.
The group discussed efforts to combat high prescription drug prices, protecting independent pharmacies and preserving access for the patients they serve.